| Lu, Heming |
NCT04157478: Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma |
|
|
| Not yet recruiting | 2 | 464 | RoW | Anlotinib Hydrochloride, Radiation therapy, Temozolomide | People's Hospital of Guangxi, First Affiliated Hospital of Guangxi Medical University, Cancer Hospital of Guangxi Medical University, Liuzhou Workers Hospital, Nanxishan Hospital, LiuZhou People's Hospital, Affiliated Hospital of Guilin University | Glioblastoma | 12/22 | 12/24 | | |
| Chen, Qi L |
NCT04667299: Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment |
|
|
| Recruiting | 4 | 270 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Amoxicillin | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 11/21 | 12/21 | | |
| Recruiting | 4 | 732 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Amoxicillin | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 12/22 | | |
NCT05018923: Tetracycline Versus Doxycycline for HP Rescue Therapy |
|
|
| Recruiting | 4 | 242 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Doxycycline, Tetracycline | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 12/22 | | |
NCT05023577: Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients |
|
|
| Recruiting | 4 | 504 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Clarithromycin, Levofloxacin | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 12/22 | | |
NCT05250050: Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment |
|
|
| Recruiting | 4 | 388 | RoW | Esomeprazole, Bismuth potassium citrate, Metronidazole, Clarithromycin, Levofloxacin, Amoxicillin, Tetracycline | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 03/23 | | |
| Recruiting | 4 | 4447 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Clarithromycin, Levofloxacin, Amoxicillin, Doxycycline, Tetracycline | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 06/26 | 06/26 | | |
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. |
|
|
| Recruiting | 3 | 192 | RoW | Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment | Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 12/24 | 12/26 | | |
NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression |
|
|
| Recruiting | 3 | 606 | RoW | Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops | Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc. | Myopia, Myopia Progression | 12/26 | 12/27 | | |
GCRP, NCT03498326: Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer |
|
|
| Recruiting | 2 | 480 | RoW | Gemcitabine, celecoxib | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Cancer, Chemotherapy Effect | 03/23 | 03/30 | | |
| Active, not recruiting | 1/2 | 21 | US | Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma | 12/24 | 12/25 | | |
NCT04682327: Gut Microbiota and Cancer Immunotherapy Response |
|
|
| Recruiting | N/A | 50 | RoW | Response to anti-PD-1/PD-L1, Non-response to anti-PD-1/PD-L1 | Shanghai Zhongshan Hospital | Non-Small Cell Lung Cancer | 12/22 | 12/22 | | |
| Completed | N/A | 126 | RoW | REMS+TAI, SEMS+TAI | Zhongda Hospital | Unresectable Hilar Cholangiocarcinoma | 07/23 | 07/23 | | |
| Not yet recruiting | N/A | 1334 | RoW | deep sedation, Conscious sedation | The First Affiliated Hospital of Dalian Medical University | Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation | 07/27 | 12/27 | | |
| Wang, Tao |
| Recruiting | 4 | 400 | RoW | Vitamin C Injection, Suicheng, H20046552, Normal saline | Kunyue Li, Third Affiliated Hospital of Zhengzhou University | Obstetric Labor Complications, Fever | 10/24 | 10/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT06049927: A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months |
|
|
| Completed | 3 | 3300 | RoW | Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV), Trivalent influenza vaccine(BY) | Sinovac Biotech Co., Ltd | Seasonal Influenza | 05/24 | 05/24 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT05726110: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 3 | 50 | RoW | Selinexor, KPT-330, Homoharringtonine, HHT, Daunorubicin, DNR, Cytarabine, Ara-C, Granulocyte Colony-Stimulating Factor, G-CSF, Aclacinomycin, ACM | Shanxi Bethune Hospital, Antengene Corporation | Relapsed or Refractory Acute Myeloid Leukemia | 12/24 | 12/24 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
NCT05402722: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Eribulin, Halaven, anti-PD-1 antibody | Beijing 302 Hospital | TNBC - Triple-Negative Breast Cancer | 12/22 | 06/23 | | |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
NCT06418594: Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis |
|
|
| Recruiting | 2 | 30 | RoW | Adebrelimab, Apatinib, Apatinib Mesylate Tablets, Etoposide, VP-16 | Beijing 302 Hospital | HER2-negative Breast Cancer Brain Metastases | 11/25 | 12/26 | | |
| Recruiting | 2 | 65 | RoW | Candonilimab, Cisplatin, Gemcitabine | West China Hospital | Cholangiocarcinoma Non-resectable | 07/25 | 07/26 | | |
| Recruiting | N/A | 1000 | RoW | Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS), Hybrid Surgery | Xuanwu Hospital, Beijing | Non-acute Carotid Artery Occlusion | 12/28 | 12/28 | | |
NCT06135194: Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib |
|
|
| Recruiting | N/A | 30 | RoW | T-DXd, DS-8201 | Beijing 302 Hospital | Breast Cancer | 12/23 | 06/24 | | |
| Recruiting | N/A | 1300 | RoW | MicRNAs battery kits | Shanghai Mental Health Center | Alzheimer Disease | 01/22 | 09/22 | | |
NCT04137926: A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease |
|
|
| Recruiting | N/A | 360 | RoW | MicRNAs battery | Shanghai Mental Health Center | Alzheimer's Disease | 08/22 | 11/22 | | |
NCT03810794: Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease |
|
|
| Recruiting | N/A | 180 | RoW | Acupuncture, Donepezil, Donepezil Hydrochloride Tablets | Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center, Huashan Hospital | Alzheimer Disease, Cognitive Impairment | 12/24 | 12/24 | | |
NCT03672448: The China Longitudinal Aging Study of Cognitive Impairment |
|
|
| Recruiting | N/A | 10000 | RoW | Naturalistic observation, Normal Aging | Shanghai Mental Health Center | Mild Cognitive Impairment, Alzheimer Disease, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Depression, Anxiety | 11/23 | 11/23 | | |
NCT06155032: Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion |
|
|
| Recruiting | N/A | 272 | RoW | Endovascular therapy, EVT group, Best medical management, Best medical management group | First Affiliated Hospital of Wannan Medical College, The First Affiliated Hospital of Anhui Medical University | Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive | 12/25 | 03/26 | | |
NCT05906719: Machine Vision Based MDS-UPDRS III Machine Rating |
|
|
| Recruiting | N/A | 871 | RoW | video recording | Ruijin Hospital, Second Affiliated Hospital of Soochow University, Beijing Hospital, Beijing Tiantan Hospital, Wuhan Union Hospital, China, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, West China Hospital | Parkinsonian Disorders, Machine Learning | 04/24 | 04/24 | | |
NCT06412107: Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors |
|
|
| Recruiting | N/A | 108 | RoW | True acupressure, Sham acupressure, Usual care | Charles Darwin University, Second Affiliated Hospital of Zunyi Medical University, Zunyi Medical College | Breast Neoplasm Female, Symptom Cluster | 02/25 | 06/25 | | |
NCT06650553: Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study |
|
|
| Recruiting | N/A | 110 | RoW | Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group. | Shanxi Bethune Hospital | Aplastic Anemias | 06/26 | 07/26 | | |
NCT05834699: HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC |
|
|
| Recruiting | N/A | 50 | RoW | HER2 expression of circulating tumor cells | Beijing 302 Hospital | Breast Cancer | 12/24 | 04/25 | | |
NCT05834686: HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC |
|
|
| Recruiting | N/A | 50 | RoW | HER2 expression of circulating tumor cells | Beijing 302 Hospital | Breast Cancer | 12/24 | 04/25 | | |
NCT05905874: Machine Learning-based Models in Prediction of DVT and PTE in AECOPD Patients |
|
|
| Recruiting | N/A | 1000 | RoW | Machine learning-based prediction model | West China Hospital, University of Chinese Academy of Sciences - Shenzhen Hospital, Affiliated Hospital of North Sichuan Medical College, Nanchong Central Hospital | Machine Learning, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease With Acute Exacerbation, Unspecified, Pulmonary Thromboembolisms, Deep Vein Thrombosis | 12/24 | 12/24 | | |
NCT05870436: A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population |
|
|
| Recruiting | N/A | 1100 | RoW | Methacholine Choline Provocation Test | jingping Zheng, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Asthma | 01/25 | 06/25 | | |
zypg001, NCT06728891: Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy |
|
|
| Not yet recruiting | N/A | 100 | RoW | In addition to routine diagnosis and treatment, no additional intervention measures were taken. | Jichao Qin | Gastric Carcinoma | 12/27 | 12/27 | | |
zytg001, NCT06728878: Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer |
|
|
| Not yet recruiting | N/A | 150 | RoW | | Jichao Qin | Gastric Cancers | 12/27 | 12/27 | | |
| Recruiting | N/A | 75 | RoW | Carotid endarterectomy (CEA), Carotid artery stenting (CAS) | Xuanwu Hospital, Beijing | Radiation-induced Carotid Artery Stenosis | 12/26 | 12/27 | | |
NCT05276713: Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor |
|
|
| Recruiting | N/A | 50 | RoW | Tucidinostat, Chidamide | Beijing 302 Hospital | Breast Cancer | 06/22 | 08/22 | | |
NCT05380999: The Red Blood Cells Based Blood Test for Lung Cancer EARLY Detection |
|
|
| Not yet recruiting | N/A | 852 | NA | Methylation tests of nucleic acids extracted from mature red blood cells (RBCs) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Peking Union Medical College Hospital, Shanghai Chest Hospital, Guangzhou Panyu Central Hospital, My-BioMed Technology （Guangzhou） Co., Ltd. | Lung Cancer, Red Blood Cells, Methylation | 03/25 | 03/26 | | |
| Zhang, Guo |
NCT06608992: Evaluation of the Effect of SURGICEL® Powder in TKA |
|
|
| Recruiting | 4 | 112 | RoW | SURGICEL® Powder | Peking University Third Hospital | Knee Osteoarthritis | 08/25 | 09/25 | | |
NCT04546360: Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004) |
|
|
| Completed | N/A | 381 | RoW | Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement. | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Tianjin Second People's Hospital, The Sixth People's Hospital of Shenyang, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, Guangxi Zhuang Autonomous Region | Compensated Advanced Chronic Liver Disease, Variceal Hemorrhage | 12/22 | 12/22 | | |
NCT05140837: Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106) |
|
|
| Recruiting | N/A | 10000 | RoW | Psychometric hepatic encephalopathy score & Stroop test, Drug therapy | Hepatopancreatobiliary Surgery Institute of Gansu Province, The First Affiliated Hospital of Anhui Medical University, Beijing Ditan Hospital, Chongqing Public Health Medical Treatment Center, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Guangxi Zhuang Autonomous Region People's Hospital, Shenzhen Third People's Hospital, Guizhou people's Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University, The Second Affiliated Hospital of Hainan Medical University, The Third Affiliated Hospital of Hebei Medical University, The Second Affiliated Hospital of Harbin Medical University, Henan Provincial People's Hospital, Ganzhou Fifth People's Hospital, The First Hospital of Jilin University, Jiangsu People's Hospital, First Hospital of China Medical University, The Second Affiliated Hospital of Baotou Medical College, Ningxia Medical University General Hospital, The Fourth People's Hospital of Qinghai Province, Xi'an High-tech Hospital, The 10th People's Hospital affiliated to Tongji University, Qilu Hospital of Shandong University, The Third People's Hospital of Taiyuan, Xichang People's Hospital, Tianjin Third Central Hospital, The Third People's Hospital of Tibet Autonomous Region, Xinjiang Autonomous Region People's Hospital, Second People's Hospital of Yunnan Province, Hangzhou Xixi hospital, LanZhou University | Hepatic Encephalopathy, Cirrhosis | 12/24 | 12/24 | | |
| Zhang, Yingjian |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) |
|
|
| Recruiting | 2 | 76 | RoW | HuHuangLianzonggan capsule, Experimental group, HuHuangLianzonggan capsule placebo, Placebo group | Tasly Pharmaceutical Group Co., Ltd | NASH | 12/24 | 12/24 | | |
| Coordinator |
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) |
|
|
| Recruiting | 4 | 12 | US | Asceniv™ | ADMA Biologics, Inc. | Primary Immune Deficiency | 03/23 | 06/23 | | |
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies |
|
|
| Recruiting | 3 | 143 | Europe, US | Intervention/Treatment | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/25 | 03/26 | | |
| Recruiting | 3 | 690 | US | Brilaroxazine, RP5063, Placebo | Reviva Pharmaceuticals | Schizophrenia | 02/25 | 02/25 | | |
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 212 | US | VRDN-001 10 mg/kg, VRDN-001 3 mg/kg | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 05/25 | 01/26 | | |
REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 84 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 03/26 | 11/26 | | |
REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 126 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 04/26 | 12/26 | | |
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 3 | 188 | Europe, US, RoW | Veligrotug (VRDN-001), Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 12/24 | 09/25 | | |
NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease |
|
|
| Recruiting | 2 | 100 | US | Carmustine 7.7Mg Wafer, GLIADEL | University of Nebraska, Arbor Pharmaceuticals, Inc. | Brain Tumor - Metastatic | 12/25 | 12/26 | | |
NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors |
|
|
| Recruiting | 2 | 200 | RoW | YL202 should be intravenously infused | MediLink Therapeutics (Suzhou) Co., Ltd. | NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors | 11/26 | 11/28 | | |
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 990 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 10/26 | 10/28 | | |
| Recruiting | N/A | 2000 | US | | Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health (NIH), University of Chicago, University of Alabama at Birmingham, Rush University, Washington University School of Medicine, Medical University of South Carolina, University Hospitals Cleveland Medical Center, Louisiana State University Health Sciences Center Shreveport, University of Florida, University of Maryland, The University of Texas Health Science Center, Houston, Ochsner Health System | Parkinson Disease | 12/26 | 12/26 | | |
NCT06186596: Self-Administered Intralesional Injections for Acne |
|
|
| Recruiting | N/A | 150 | US | Triamcinolone delivered via injection assistance device | ACOM Labs | Acne Vulgaris | 01/24 | 01/24 | | |
NCT05879198: Train Your Brain: A Pilot Project to Improve Memory and Decision Making |
|
|
| Completed | N/A | 24 | US | Computer-based Intervention | Henry Ford Health System, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Behavior, Health | 09/23 | 09/23 | | |
PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD |
|
|
| Recruiting | N/A | 1410 | US | | Aqtual, Inc. | Rheumatoid Arthritis | 06/25 | 12/25 | | |
NCT04642898: Increasing Treatment Efficacy Using SMART Methods for Personalizing Care |
|
|
| Completed | N/A | 66 | US | Standard UP Treatment, Capitalization UP Treatment, Compensation UP Treatment | Shannon E. Sauer-Zavala, National Institute of Mental Health (NIMH) | Anxiety Disorders, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder | 06/24 | 06/24 | | |
NCT03594994: Metabolic Effects of Sleep Extension in People With Obesity |
|
|
| Completed | N/A | 40 | US | Sleep extension | Washington University School of Medicine | Insulin Resistance, Obesity | 07/24 | 07/24 | | |
NCT06242704: Train Your Brain 2.0 - Improving Memory and Decision Making Among Youth |
|
|
| Recruiting | N/A | 72 | US | Working Memory Training, Working Memory | Henry Ford Health System | Behavior, Health | 08/26 | 08/26 | | |
NCT04587518: Five Factor Model Treatment for Borderline Personality Disorder |
|
|
| Completed | N/A | 100 | US | Personality-Based Cognitive Behavioral Therapy | Shannon E. Sauer-Zavala | Borderline Personality Disorder | 05/24 | 05/24 | | |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 03/25 | 03/25 | | |
ELEVATE-HF, NCT06592508: Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure |
|
|
| Recruiting | N/A | 180 | US | Remote Virtual Cardiology Program | Duke University, Ventricle Health | Heart Failure; With Decompensation | 08/26 | 08/26 | | |
NCT03701828: Liver Health and Metabolic Function in People With Obesity |
|
|
| Enrolling by invitation | N/A | 30 | US | Weight loss surgery, Sleeve gastrectomy, Roux-en-Y, biliopancreatic diversion | Washington University School of Medicine | Non-Alcoholic Fatty Liver Disease | 11/24 | 03/25 | | |
| Recruiting | N/A | 87 | US | Telemedicine | University of Pennsylvania | Psoriatic Arthritis | 02/25 | 02/25 | | |
| Recruiting | N/A | 200 | Europe | Modified prolonged exposure, Brief intervention, cognitive behavioral therapy | St. Olavs Hospital, Norwegian University of Science and Technology, The Research Council of Norway, Norwegian Women's Public Health Association (Norske Kvinners Sanitetsforening), National Centre for Emergency Primary Health Care, NORCE, UiT The Arctic University of Norway | Post Traumatic Stress Disorder, Rape Sexual Assault, Sexual Dysfunctions, Psychological, Pelvic Floor Myalgia, Pelvic Pain Syndrome, Depression, Anxiety, Sleep Disturbance, Activity, Motor, Cortisol Deficiency | 05/25 | 12/27 | | |
| Recruiting | N/A | 506 | US | CHOICES, eBook | University of Florida, National Human Genome Research Institute (NHGRI) | Sickle Cell Disease, Sickle Cell Trait | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 220 | US | EXTEND Plus, EXTEND | Duke University, National Institute of Nursing Research (NINR) | Diabetes Mellitus, Type 2, Hypertension | 10/25 | 10/25 | | |
| Chen, Jia-xin |
NCT03468010: A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) |
|
|
| Recruiting | 3 | 432 | RoW | chemoradiation, Paclitaxel, Cisplatin | Sun Yat-sen University | Cervical Cancer, Adjuvant Chemotherapy, Radiation, Lymph Node Metastases | 03/25 | 03/25 | | |
NCT03071289: A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer |
|
|
| Recruiting | 3 | 540 | RoW | Radiation Method B, Cisplatin, Radiation Method A | Sun Yat-sen University | Cervical Cancer, Lymphocyst, Radiation Therapy | 03/25 | 03/25 | | |
| Lin, Ren |
NCT04203108: ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis |
|
|
| Recruiting | 4 | 266 | RoW | ATG, CsA, MTX, MMF | Nanfang Hospital of Southern Medical University | Hematopoietic Stem Cell Transplantation | 08/21 | 12/22 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Recruiting | 2 | 152 | RoW | Mesenchymal stem cells, Glucocorticoids, cyclosporine | Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Xinqiao Hospital, Army Medical University, Peking University People's Hospital | Chronic Graft-versus-host Disease | 12/22 | 06/23 | | |
| Completed | 2 | 77 | RoW | CD19-CAR-T2 Cells | Nanfang Hospital, Southern Medical University | B Cell Leukemia, B Cell Lymphoma | 06/23 | 12/23 | | |
ABC, NCT06220487: A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL |
|
|
| Recruiting | 2 | 67 | RoW | Prednisone, Olverembatinib, Blinatumomab, Chidamide | Nanfang Hospital, Southern Medical University | Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL, IKZF1 Gene Mutation | 12/25 | 01/28 | | |
NCT04747093: Induced-T Cell Like NK Cells for B Cell Malignancies |
|
|
| Recruiting | 1/2 | 12 | RoW | CAR-ITNK cells | Nanfang Hospital of Southern Medical University | B Cell Leukemia, B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | 12/21 | 03/22 | | |
| Chen, Kehe |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
| Recruiting | N/A | 200 | RoW | Anlotinib | Guangxi Zhuang Autonomous Region People's Hospital | Liver Neoplasms | 07/23 | 07/24 | | |
| Jin, Ping |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
NCT06350812: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects |
|
|
| Active, not recruiting | 1/2 | 32 | RoW | PB-119, Placebo | PegBio Co., Ltd. | Obesity | 04/25 | 04/25 | | |
MASLD, NCT06441409: Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease |
|
|
| Completed | N/A | 185 | RoW | Lifestyle intervention | The Third Xiangya Hospital of Central South University | Nonalcoholic Fatty Liver Disease, Fertility Disorders | 04/23 | 04/23 | | |
| Recruiting | N/A | 7 | RoW | prone position | Seventh Medical Center of PLA General Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Xian Children's Hospital, People's Hospital of Guangxi, Henan Provincial People's Hospital, Guangdong Provincial People's Hospital, Shenzhen Bao'an Maternal and Child Health Hospital, Zhengzhou Children's Hospital | Pediatric Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation | 05/25 | 07/25 | | |
NCT05500118: Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU |
|
|
| Recruiting | N/A | 120 | RoW | Patients Decision Aids | Shenzhen Maternity & Child Healthcare Hospital | Leiomyoma, Uterine, High-Intensity Focused Ultrasound Ablation, Patients Decision Aids | 08/24 | 08/27 | | |
| Han, Lin |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
FAVOR IV-QVAS, NCT03977129: Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease |
|
|
| Active, not recruiting | N/A | 792 | RoW | QFR-guided strategy, CAG-guided strategy | Ruijin Hospital, Med-X Research Institute, Shanghai Jiao Tong University | Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease | 09/24 | 12/26 | | |
| Not yet recruiting | N/A | 648 | RoW | Posterior Pericardiotomy | Changhai Hospital | Atrial Fibrillation (AF), Cardiac Events | 12/25 | 06/26 | | |
| Zhou, Hua |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013) |
|
|
| Active, not recruiting | 2 | 73 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 07/25 | 09/25 | | |
